Clinical Trials Logo

Clinical Trial Summary

This is a research study to find out if a hormone called progesterone affects marijuana users' stress response and marijuana use. Progesterone is a naturally occurring sex hormone involved in the menstrual cycle and reproduction, and has been shown to reduce withdrawal symptoms when people stop using substances like cocaine and nicotine. It is not FDA approved for treating cannabis users and is considered an investigational drug in this study.


Clinical Trial Description

Participants will complete a screening visit to determine study eligibility. Eligible subjects will be scheduled to begin 22 days of study participation. During the first week, participants will be randomly assigned to take either progesterone or placebo (inactive medication) twice a day, and to abstain from marijuana use. During this week, participants will upload videos of themselves taking their medication and performing saliva drug tests. They will collect and store additional saliva samples each morning for hormone testing. They will also participate in "CREMA" sessions (Cue Reactivity Ecologic Momentary Assessment) three times a day. These sessions include looking at stressful and neutral pictures and rating stress and craving. At the end of this week, participants will return to the clinic and participate in a stress task. For the next two weeks, participants will continue to collect saliva samples and participate in CREMA sessions. They will return at the end of the two weeks to return study supplies. Urine samples will be collected at each study visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03729869
Study type Interventional
Source Medical University of South Carolina
Contact
Status Completed
Phase Phase 2
Start date January 18, 2019
Completion date November 9, 2022

See also
  Status Clinical Trial Phase
Completed NCT03253926 - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Phase 1/Phase 2
Completed NCT04060602 - Personalized Feedback Intervention to Reduce Risky Cannabis Use. N/A
Completed NCT01212081 - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting NCT04988490 - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting NCT05188404 - Aging and Marijuana: Benefits, Effects, and Risks
Completed NCT03662737 - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting NCT04374773 - Effects of Pregnancy-associated Hormones on THC Metabolism in Women Phase 4
Completed NCT04316741 - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use N/A
Recruiting NCT05396638 - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder N/A
Recruiting NCT05309226 - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting NCT03859089 - Cannabis for Opioid Substitution Trial
Recruiting NCT05849636 - Alerta Cannabis: Evaluation of Web-based Tailored Intervention N/A
Enrolling by invitation NCT05521321 - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit N/A
Recruiting NCT05119244 - Environment and Lung Cancer N/A
Recruiting NCT04841655 - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated NCT04100590 - Eye Tracking as a Biomarker of Cannabis Effects Phase 2
Completed NCT05167097 - Mindsets and the Effectiveness of a Brief Intervention - Replication N/A
Recruiting NCT04114903 - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity